ReviewFrontiers in immunology2025
Metabolic regulation of interferon-mediated innate antiviral immunity.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- ATG13 promotes K63-linked polyubiquitination of MAVS via ASB1 to restrict influenza A virus replication.Emerging microbes & infections · 2026Article
- Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.Inflammopharmacology · 2026Review
- Distinct Transcriptomic Signatures of HIV-1 Tat and gp120 Uncover Differential Neuroimmune Vulnerability in aCurrent issues in molecular biology · 2026Article
- AI-driven big data analysis and predictive modeling of infectious disease immunity: from correlates to causal, multiscale understanding.Archives of microbiology · 2026Review
- The Diabetes-Viral Respiratory Syndemic: Pathophysiological Insights and Precision Management: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
- Beyond Viral Restriction: The Metabolic Dimensions of Interferon-Stimulated Genes in Antiviral Immunity.Viruses · 2026Review
- Molecular Dissection of Permanent vs. Reperfused Ischemia: Multi-Omics Divergence and Precision Therapeutic Implications.Current issues in molecular biology · 2026Article
- Convergent hub pathways targeted by IAV, SARS-CoV-2, and RSV in type II alveolar epithelial cells: molecular mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viral infections pose a major global public health challenge, with pathogens such as influenza viruses, novel coronaviruses, and respiratory syncytial virus exerting serious threats to human health. These infections often progress to severe disease in children, the elderly, and individuals with compromised immunity. Due to their anatomical exposure and relatively weak mucosal defenses, the upper respiratory tract-including the nasal cavity and throat-serves as a primary portal of entry for these pathogens. Such infections can lead to otolaryngological conditions such as anosmia and otitis media, and may further exacerbate illness in susceptible populations. After viral invasion, the host perceives pathogens through pattern recognition receptors (PRRs), rapidly activating the expression and signaling pathways of type I and type III interferons (IFN). This plays a core role in antiviral defense. Notably, viral infection profoundly reshapes the host cell's metabolic network, involving widespread alterations in carbohydrate, lipid, amino acid, and nucleotide metabolism. During this process, key metabolic products are released or generated. These are the products of metabolic reprogramming and important immune regulatory molecules that can directly or indirectly modulate the host's antiviral immune response, particularly the interferon pathway. These findings reveal that viral invasion, host metabolic reprogramming, and interferon-mediated antiviral immunity form a tightly intertwined, and dynamically interact a regulatory network of"virus-metabolism-IFN". This profoundly elucidates the underlying regulatory logic of the metabolic microenvironment in antiviral immunity. Understanding this mechanism offers new perspectives for diagnosis and treatment: targeting metabolic nodes or utilizing metabolic modulators, as well as combined strategies with IFN, and may become novel approaches for the prevention and treatment of upper respiratory viral diseases. This review focuses on the core role of IFN-mediated innate immunity in viral defense and its interactive regulation with metabolic reprogramming. It reviews the progress of studies on how metabolic products regulate the IFN pathway and antiviral responses through various mechanisms, and explores the potential clinical application prospects of metabolic regulation in local immune defense and the prevention and treatment of viral infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.